ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NSTM NovelStem International Corp (PK)

0.0601
0.0001 (0.17%)
May 21 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 5,000
Bid Price 0.0601
Ask Price 0.078
News -
Day High 0.0601

Low
0.06

52 Week Range

High
0.2768

Day Low 0.0601
Company Name Stock Ticker Symbol Market Type
NovelStem International Corp (PK) NSTM OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0001 0.17% 0.0601 09:30:00
Open Price Low Price High Price Close Price Prev Close
0.0601 0.0601 0.0601 0.0601 0.06
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1 5,000 $ 0.0601 $ 301 - 0.06 - 0.2768
Last Trade Time Type Quantity Stock Price Currency
09:30:00 5,000 $ 0.0601 USD

NovelStem International Corp (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.82M 46.88M - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NovelStem (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NSTM Message Board. Create One! See More Posts on NSTM Message Board See More Message Board Posts

Historical NSTM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.06010.000.0000.000.00%
1 Month0.060.06010.060.062000.00010.17%
3 Months0.0610.070.060.06022082,548-0.0009-1.48%
6 Months0.0980.0980.060.068319611,625-0.0379-38.67%
1 Year0.19860.27680.060.120375311,284-0.1385-69.74%
3 Years0.3250.350.03250.221110326,375-0.2649-81.51%
5 Years0.1050.350.03250.158169832,414-0.0449-42.76%

NovelStem (PK) Description

NovelStem owns a 33% stake in NewStem Ltd. which is advancing its novel stem-cell-based diagnostic technology for predicting patients resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical therapies. NovelStem recently increased its ownership to 33% from 27.3% based upon completion of an additional $1M investment on top of $3M that was invested prior, for a total investment of $4M in NewStem. NovelStem also has a 50% stake in Netco Partners, which owns the Net Force publishing franchise. NewStem is advancing novel stem-cell-based technology utilized for the development of new diagnostics and therapeutics. The most advanced product of NewStem is a diagnostic predicting patients resistance to cancer therapy, allowing for better, targeted personal-oncology treatments with the potential to reduce incidents of anti-cancer drug resistance. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalems technology-transfer company. NewStems diagnostic solutions are based on the research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells & Genetic Research at Hebrew University. NewStem holds the intellectual property, reagents & experience required for hHPSC isolation, differentiation, genetic manipulation, immunogenicity & tumorigenicity.

Your Recent History

Delayed Upgrade Clock